CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix. In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn's inventories of leronlimab are actually building up, whether they'll ever be being used is an open question.


While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. The 1st CytoDyn article of mine, "CytoDyn: What In order to Do When It's Too Good To Be True?", set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire job interview which I came away with a poor viewpoint of the company.

Irony of irony, the bad opinion of mine of the company has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today's payment of $3.5 zillion transfers ownership of this expertise and associated intellectual property coming from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance.... milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) along with the very first brand new drug application endorsement ($five million), and even royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn's guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it's this single treatment and a "broad pipeline of indications" as it puts it. I call certain pipelines, "pipedots." In CytoDyn's situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple presentations.

Can all this be smoke cigarettes and mirrors? That is a question I have been asking myself through the very beginning of the interest of mine in this organization. Judging by way of the multiples of a huge number of various responses on listings accessible through Seeking Alpha's CytoDyn Summary webpage, I'm much from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *